Assembly Biosciences, Inc. (NASDAQ:ASMB) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 04:30 pm ET
Good afternoon and welcome to the Assembly Biosciences HBV Portfolio Progress Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, after the prepared remarks. As a reminder, this conference call is being recorded.
I would now like to turn the call over to Amy Figueroa, Interim Investor Relations Consultant for Assembly. Please go ahead.
Good afternoon and thank you for joining us. As we discussed the recent progress with Assembly's portfolio of clinical stage core inhibitors, which are advancing in development for the treatment of patients with chronic hepatitis B infection.
This afternoon, we issued a press release reporting our financial results for the first quarter of 2020, and providing a corporate update. This press release and the slides we will refer to during the call are available in the news and events section of our corporate website at www.assemblybio.com. After our prepared remarks, a PDF of the slides will be available from our website.
Also a replay of today's call and webcast will be available from our website. In a moment, I will turn the call over to Dr. John McHutchison, Assembly, Bio's Chief Executive Officer and President to provide a corporate update and the virologic response criteria or stopping criteria, which will be used to determine which patients begin coming off of therapy in study later this year.
Then Dr. Luisa Stamm, Chief Medical Officer will review the criteria in more detail and provide an overview of the abstract accepted for presentation at the virtual EASL meeting August 27th through 29th including data on our lead core inhibitor 731, second generation core inhibitor 2158 and our highly sensitive assays.
Finally, John, Luisa, Dr. Richard Colonno, our Executive Vice President and Chief Scientific Officer of Virology; and Tom Russo, Our Chief Financial Officer will be available for the Q&A portion of the call.
Before we begin, I want to remind you that, we will be making forward looking statements, including statements regarding our future research and development plans, evaluation of interim data, the timing of clinical trials, trial results and therapeutic potential of our development programs.
These statements are subject to the Safe Harbor protections provided under the Private Securities Litigation Reform Act of 1995, involves certain assumptions, risks and uncertainties that are beyond our control and actual results may differ materially from these forward-looking statements.
A description of these risks can be found in Slide 3 as well as our latest SEC disclosure documents and press releases. Assembly does not undertake any obligation to update any forward-looking statements made during this call.
I'll now hand the call over to Assembly's CEO, Dr. John McHutchison.
Thanks, Amy, and welcome to everyone on the call today. I'm pleased to be speaking with you all again. Whilst we had planned to be doing this in person at EASL in London a few weeks ago, we're happy to now provide you a broader corporate update coinciding with the end of the quarter along